Evidence map›Paper›PMID 17686378›Full record

ReviewCurrent hypertension reports2007

Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Thor Tejada, Alessia Fornoni, Oliver Lenz, Barry J Materson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Thor TejadaDivision of Nephrology and Hypertension, Department of Medicine, Miller School of Medicine, University of Miami OPPRP (D-54), PO Box 016960, Miami, FL 33101, USA.
Alessia Fornoni
Oliver Lenz
Barry J Materson
University of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amlodipine is a highly effective and safe antihypertensive dihydropyridine calcium channel blocker. It is even more effective when used in combination with other antihypertensive medications, including hydrochlorothiazide. When antihypertensive calcium channel blockers were first introduced, evidence in the laboratory that they had some natriuretic properties was adduced to suggest that they would be "the diuretics of the 1990s." This turned out not to be the case. Because of its clinical efficacy, amlodipine is frequently used in fixed-dose combination products, but it is not likely to replace hydrochlorothiazide.

Indexed as

AmlodipineAntihypertensive AgentsCalcium Channel BlockersDiureticsDrug Therapy, CombinationHumansHydrochlorothiazideHypertensionRandomized Controlled Trials as TopicRenin-Angiotensin SystemAmlodipineAntihypertensive AgentsCalcium Channel BlockersDiureticsHydrochlorothiazide

Identifiers

PMID17686378
OpenAlexW2156577489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.